Drug Profile
TKD activated natural killer cells - Alphageneron Pharmaceuticals/multimmune
Alternative Names: Activated autologous NK cells - multimmune; Enkastim-ev; Enkastim-iv; Heat shock protein 70 peptide activated natural killer cells; HSP70 peptide activated natural killer cells; Hsp70-peptide TKD/IL-2 activated, autologous NK cells; Natural killer cell therapy - multimmuneLatest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator multimmune
- Developer Alphageneron Pharmaceuticals; multimmune; Technical University Munich
- Class Antineoplastics; Cell therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
- No development reported Colorectal cancer
Most Recent Events
- 10 Apr 2024 Preclinical trials in Non-small cell lung cancer in USA (IV) (Alphageneron Pharmaceuticals Pipeline, April 2024)
- 10 Apr 2024 Alphageneron Pharmaceuticals plans a phase I trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) in future (Alphageneron Pharmaceuticals Pipeline, April 2024)
- 18 Oct 2021 Alphageneron Pharmaceuticals plans phase II trial in Non-small cell lung cancer (Late-stage disease) in 2022